Get the Stockscreener App
3.80
3.06%
-0.12
After Hours:
3.76
-0.04
-1.05%
Athira Pharma Inc stock is traded at $3.80, with a volume of 16,534.
It is down -3.06% in the last 24 hours and up +897.38% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$3.92
Open:
$3.92
24h Volume:
16,534
Relative Volume:
0.11
Market Cap:
$15.46M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-1.2298
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-8.21%
1M Performance:
+897.38%
6M Performance:
+1,488%
1Y Performance:
+804.55%
1-Day Range:
$3.80
$4.04
1-Week Range:
$3.80
$4.59
52-Week Range:
$0.2195
$4.59
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
3.80 | 15.46M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Key metrics from Athira Pharma Inc.’s quarterly data2025 Market Overview & Free Real-Time Volume Trigger Notifications - newser.com
Analyzing recovery setups for Athira Pharma Inc. investors2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com
Will Athira Pharma Inc. stock sustain high P E ratiosJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
What recovery options are there for Athira Pharma Inc.2025 Top Gainers & Technical Pattern Alert System - newser.com
Real time scanner hits for Athira Pharma Inc. explainedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - newser.com
Measuring Athira Pharma Inc.’s beta against major indicesWeekly Investment Recap & Smart Swing Trading Alerts - newser.com
Is Athira Pharma Inc. forming a bottoming baseJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
Is it time to cut losses on Athira Pharma Inc.2025 Dividend Review & Reliable Breakout Stock Forecasts - newser.com
Is Athira Pharma Inc. still worth holding after the dipChart Signals & High Win Rate Trade Tips - newser.com
News impact scoring models applied to Athira Pharma Inc.Weekly Trade Report & Real-Time Buy Zone Alerts - newser.com
Quantitative breakdown of Athira Pharma Inc. recent moveJuly 2025 Reactions & Community Supported Trade Ideas - newser.com
Multi factor analysis applied to Athira Pharma Inc.July 2025 News Drivers & Accurate Entry and Exit Point Alerts - newser.com
Will Athira Pharma Inc. price bounce be sustainableWeekly Investment Recap & Reliable Breakout Forecasts - newser.com
What institutional flow reveals about Athira Pharma Inc.Rate Cut & Low Risk Growth Stock Ideas - newser.com
Regression analysis insights on Athira Pharma Inc. performance2025 Analyst Calls & AI Enhanced Execution Alerts - newser.com
Full technical analysis of Athira Pharma Inc. stockWatch List & Free Expert Verified Stock Movement Alerts - newser.com
Athira Pharma regains Nasdaq compliance after meeting minimum bid requirement - Investing.com
Building trade automation scripts for Athira Pharma Inc.July 2025 Review & Risk Controlled Swing Trade Alerts - newser.com
Will Athira Pharma Inc. see short term momentumEarnings Overview Summary & AI Driven Stock Movement Reports - newser.com
Published on: 2025-10-02 23:40:16 - newser.com
Published on: 2025-10-02 21:18:52 - newser.com
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):